WEBULL
News
CMND
1.120
+2.75%
0.030
Psychedelic: Clearmind reports additional CMND-100 safety results
TipRanks · 2d ago
Clearmind Medicine Issues $2.5 Million in Convertible Notes at $1.25 Floor Price
Reuters · 3d ago
Clearmind Medicine announces additional safety results on CMND-100
TipRanks · 5d ago
Clearmind Medicine Announces Additional Safety Topline Results From Second Cohort Of Ongoing FDA-Approved Phase I/Iia Clinical Trial Evaluating CMND-100, Proprietary Non-Hallucinogenic MEAI-Based Oral Drug Candidate, For AUD Treatment
Benzinga · 5d ago
Clearmind Medicine meldet positive Sicherheitsergebnisse für CMND-100 in klinischer Studie gegen Alkoholabhängigkeit
Reuters · 5d ago
Clearmind Medicine Reports Positive Safety Results for CMND-100 in Alcohol Use Disorder Trial
Reuters · 5d ago
CLEARMIND MEDICINE INC - SAFETY DATA SHOW NO SERIOUS ADVERSE EVENTS IN SECOND COHORT
Reuters · 5d ago
Weekly Report: what happened at CMND last week (0202-0206)?
Weekly Report · 5d ago
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
Barchart · 5d ago
Clearmind Medicine kooperiert mit Polyrizon zur Entwicklung einer intranasalen MEAI-Formulierung
Reuters · 02/06 14:53
Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders
NASDAQ · 02/06 14:36
BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery
Reuters · 02/06 13:25
Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation
TipRanks · 02/06 13:00
Clearmind Engages Polyrizon To Apply Proprietary Intranasal Hydrogel Technology To Develop Optimized Formulation Of Clearmind's MEAI For Treatment Of Addiction-Related Disorders, Weight Loss And Other CNS Conditions
Benzinga · 02/06 12:57
CLEARMIND MEDICINE ENTERS INTO DEVELOPMENT AGREEMENT TO ADVANCE INTRANASAL FORMULATION FOR ITS PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN MEAI
Reuters · 02/06 12:55
Clearmind Medicine schließt Entwicklungsvereinbarung mit Polyrizon zur intranasalen Formulierung von MEAI
Reuters · 02/06 12:55
Clearmind Medicine Signs Development Agreement with Polyrizon for Intranasal MEAI Formulation
Reuters · 02/06 12:55
Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation
Reuters · 02/06 12:55
POLYRIZON SIGNS AN AGREEMENT TO DEVELOP INTRANASAL PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN FORMULATION
Reuters · 02/06 12:55
Psychedelic: Analyst initiates Definium, Helus with Buy ratings
TipRanks · 02/05 15:40
More
Webull provides a variety of real-time CMND stock news. You can receive the latest news about Clearmind Medici through multiple platforms. This information may help you make smarter investment decisions.
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.